Preliminary evidence implies that miR171vr, whether introduced through diet or as a supplement in gene therapies, might potentially have an impact on human gene expression, particularly in the treatment of disorders where GNA12 is overexpressed (such as oral cancer, breast, and prostate adenocarcinoma) or mTOR kinase is downregulated (for example, obesity, type 2 diabetes, and neurodegeneration) [48]. This evidence concerns the gene GNA12 and lip and oral cavity carcinoma.